Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Muhammad Fayyaz ur Rehman, Chaudhary Fariha, Aqsa Anwar, Naveed Shahzad, Salma Mukhtar, Muhammad Farhan Ul Haque
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
10.3390/v11030210
10.3390/v11030210
10.1016/s0140-6736(20)30251-8
10.1016/s0140-6736(20)30251-8
10.1016/s0140-6736(20)30185-9
10.1016/s0140-6736(20)30185-9
SARS pandemic and the 2020 novel coronavirus epidemic in China
2003
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet
2020
A genomic perspective on the origin and emergence of SARS-CoV-2
2020
Asymptomatic cases in a family cluster with SARS-CoV-2 infection
10.1016/s1473-3099(20)30114-6 · 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges
2020
A review of coronavirus disease-2019 (COVID-19)
2020
Coronavirus disease: A review of a new threat to public health
2020
Emerging coronaviruses: genome structure, replication, and pathogenesis
10.1002/jmv.26234 · 2020
A new virus isolated from the human respiratory tract
10.3181/00379727-121-30734 · 1966
Growth in suckling-mouse brain of“ IBV-like” viruses from patients with upper respiratory tract disease
10.1073/pnas.58.6.2268 · 1967
Bat origin of human coronaviruses
2015
10.1038/cr.2013.92
10.1038/cr.2013.92
A rapid and specific assay for the detection of MERS-CoV
10.3389/fmicb.2018.01101 · 2018
Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China
10.1186/s13054-020-02895-6 · 2020
Emerging Manufacturers engagements in the COVID-19 vaccine research, development and supply
10.1016/j.vaccine.2020.06.022 · 2020
10.1038/s41591-020-0820-9
10.1038/s41591-020-0820-9
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV
2020
Coronavirus disease (COVID-19) and prevalence of chronic liver disease: A meta-analysis
2019
Epidemiological characteristics of COVID-19: a systematic review and meta-analysis
10.1017/s0950268820001430 · 2020
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
10.1016/s2213-8587(20)30238-2 · 2020
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet
2020
The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020
10.46234/ccdcw2020.032 · 2020
Coronavirus disease 2019 and gender-related mortality in European countries: A meta-analysis
10.1016/j.maturitas.2020.06.017 · 2020
Singapore COVID-19 pandemic response as a successful model framework for low-resource health care settings in Africa? OMICS: A Journal of
2020
Unresolved referenced work
Kept as external metadata until matched
Estimation of exponential growth rate and basic reproduction number of the coronavirus disease 2019 (COVID-19) in Africa
10.1186/s40249-020-00718-y · 2020
10.1038/s41564-020-0695-z
10.1038/s41564-020-0695-z
Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses
2020
History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic
2020
10.1038/s41586-020-2012-7
10.1038/s41586-020-2012-7
Possible bat origin of severe acute respiratory syndrome coronavirus 2
10.3201/eid2607.200092 · 2020
10.1016/j.meegid.2020.104212
10.1016/j.meegid.2020.104212
Molecular evolution and phylogenetic analysis of SARS-CoV-2 and hosts ACE2 protein suggest Malayan pangolin as intermediary host
2020
Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence
2020
10.1016/j.meegid.2020.104351
10.1016/j.meegid.2020.104351
10.1136/bmj.m4857
10.1136/bmj.m4857
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
10.1016/j.cell.2020.08.012 · 2020
10.1016/j.jconrel.2015.08.007
10.1016/j.jconrel.2015.08.007 · doi-reference
Dexamethasone nanomedicines for COVID-19
10.1038/s41565-020-0752-z · doi-reference
10.2217/nnm-2020-0286
10.2217/nnm-2020-0286 · doi-reference
10.1016/j.nantod.2020.101019
10.1016/j.nantod.2020.101019 · doi-reference
10.1136/bmj.m1679
10.1136/bmj.m1679 · doi-reference
BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies
10.1016/j.jaci.2014.02.028 · doi-reference
10.1126/science.abb2507
10.1126/science.abb2507 · doi-reference
Coronavirus vaccines: five key questions as trials begin
10.1038/d41586-020-00798-8 · doi-reference
10.1073/pnas.2006961117
10.1073/pnas.2006961117 · doi-reference
10.1001/jama.2020.10699
10.1001/jama.2020.10699 · doi-reference
Interferon beta-1b for COVID-19
10.1016/s0140-6736(20)31101-6 · doi-reference
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
10.1128/aac.00754-20 · doi-reference
10.1136/annrheumdis-2020-218122
10.1136/annrheumdis-2020-218122 · doi-reference
Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective
10.7150/ijbs.45538 · doi-reference
10.1159/000069334
10.1159/000069334 · doi-reference
Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis
10.1046/j.1440-1746.2002.02876.x · doi-reference
10.20944/preprints202003.0349.v1
10.20944/preprints202003.0349.v1 · doi-reference
Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2
10.1038/s41598-020-74715-4 · doi-reference
Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review
10.1002/ptr.6178 · doi-reference
10.1056/nejmoa2001282
10.1056/nejmoa2001282 · doi-reference
10.1021/acscentsci.0c00272
10.1021/acscentsci.0c00272 · doi-reference
Favipiravir, an antiviral for COVID-19?
10.1093/jac/dkaa171 · doi-reference
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
10.1016/j.jiph.2020.07.013 · doi-reference
10.1101/2020.04.10.20060558
10.1101/2020.04.10.20060558 · doi-reference
Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
10.1016/j.therap.2020.05.010 · doi-reference
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
10.1186/1743-422x-2-69 · doi-reference
10.1099/jgv.0.000309
10.1099/jgv.0.000309 · doi-reference
10.3390/v8120322
10.3390/v8120322 · doi-reference
Chloroquine interferes with dengue-2 virus replication in U937 cells
10.1111/1348-0421.12154 · doi-reference
10.1007/s00535-009-0132-9
10.1007/s00535-009-0132-9 · doi-reference
Effects of chloroquine on viral infections: an old drug against today's diseases
10.1016/s1473-3099(03)00806-5 · doi-reference
10.1038/cr.2012.165
10.1038/cr.2012.165 · doi-reference
New insights into the antiviral effects of chloroquine
10.1016/s1473-3099(06)70361-9 · doi-reference
Type I and Type III Interferons-Induction, Signaling, Evasion, and Application to Combat COVID-19
10.1016/j.chom.2020.05.008 · doi-reference
10.1172/jci138745
10.1172/jci138745 · doi-reference
10.1016/s1473-3099(20)30141-9
10.1016/s1473-3099(20)30141-9 · doi-reference
10.1001/jama.2020.10245
10.1001/jama.2020.10245 · doi-reference
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department
10.1002/jmv.25800 · doi-reference
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
10.2807/1560-7917.es.2020.25.16.2000421 · doi-reference
Development and validation of a rapid, single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19
10.3389/fcimb.2020.00331 · doi-reference